M

Mid-Atlantic Epilepsy and Sleep Center | Bethesda, MD

Research site
(Unclaimed)
Location
6410 Rockledge Drive, Suite 610, Bethesda, Maryland, United States of America

Site insights

Top conditions

Top treatments

XEN1101
Cenobamate
Eslicarbazepine Acetate
YKP3089
Retigabine
ZX008
Ganaxolone
Fenfluramine Hydrochloride
Perampanel
LP352

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

17 of 44 total trials

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE2)

The X-TOLE2 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and toler...

Enrolling
Focal Onset Seizures
Drug: XEN1101
Drug: Placebo

This study was designed to evaluate the safety, tolerability, pharmacodynamics (PD) of DS-1211b, and pharmacokinetics (PK) in individuals with Pseudo...

Active, not recruiting
Pseudoxanthoma Elasticum
Drug: DS-1211b
Other: Placebo

The XEN1101 Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and toler...

Active, not recruiting
Focal Epilepsy
Drug: XEN1101

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN...

Enrolling
Primary Generalized Tonic-Clonic Seizures
Drug: Placebo
Drug: XEN1101

This is a two-part, multicenter, double-blind, parallel-group, placebo controlled study to evaluate the effect of ZX008 when used as adjunctive thera...

Active, not recruiting
Lennox Gastaut Syndrome
Drug: Matching Placebo
Drug: ZX008 0.2 or 0.8 mg/kg/day

This is an international, multicenter, open-label, long-term safety study of ZX008 in subjects with Dravet syndrome, Lennox-Gastaut syndrome or epile...

Active, not recruiting
Epileptic Encephalopathy
Dravet Syndrome
Drug: ZX008 (Fenfluramine Hydrochloride)

Researchers are looking for a better way to prevent an ischemic stroke which occurs when a blood clot travelled to the brain in people who within the...

Enrolling
High-risk Transient Ischemic Attack
Acute Non-cardioembolic Ischemic Stroke
Drug: Placebo
Drug: Asundexian (BAY2433334)

This is a Phase 3, global, double-blind, randomized, placebo-controlled study of adjunctive GNX treatment in children and adults with TSC-related epi...

Active, not recruiting
Tuberous Sclerosis Complex
Drug: Ganaxalone
Drug: Placebo

This study will evaluate the long term safety, tolerability, PK, and efficacy of XEN1101 25 mg QD taken orally in subjects with Focal Onset Seizures...

Invitation-only
Tonic-Clonic Seizures
Focal Epilepsy
Drug: XEN1101

52 Week Open-Label Safety Study of Cenobamate for Subjects who Complete YKP3089C025 (core study)

Invitation-only
Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized Epilepsy
Drug: Cenobamate

The primary objective of this study is to assess the pharmacokinetics of cenobamate (YKP3089) in pediatric subjects with partial-onset (focal) seizur...

Enrolling
Partial Epilepsy
Drug: Xcopri

The primary objective is to evaluate the efficacy of carisbamate (YKP509) as adjunctive treatment in reducing the number of drop seizures (tonic, ato...

Enrolling
Seizures
Lennox Gastaut Syndrome
Drug: Carisbamate

This is a Phase 3, global, open-label extension (OLE) study of adjunctive GNX treatment in children and adults with TSC who previously participated i...

Invitation-only
Tuberous Sclerosis Complex
Drug: Ganaxolone

The objective of this study is to assess the long-term safety, tolerability, and efficacy of adjunctive therapy of LP352 in subjects with development...

Enrolling
Developmental and Epileptic Encephalopathy
Lennox-Gastaut Syndrome
Drug: LP352

This trial is intended to study the safety and effectiveness of an new anti-epileptic drug (AED) on Primary Generalized Tonic-Clonic (PGTC) Seizures....

Enrolling
Primary Generalized Epilepsy
Drug: Placebo
Drug: Cenobamate

Primary objective: To evaluate the safety and tolerability of cenobamate in pediatric subjects 2-17 years of age with partial-onset (focal) seizures

Enrolling
Partial Epilepsy
Drug: Xcopri

This is a double-blind, placebo controlled, randomized study of dose-ranging safety, tolerability, exploratory efficacy of adjunctive EQU-001 for sei...

Active, not recruiting
Epilepsy
Drug: Placebo
Drug: EQU-001

Trial sponsors

SK Life Science logo
M
X
Eisai logo
GlaxoSmithKline (GSK) logo
Sumitomo Pharma logo
M
E
L
Lundbeck logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems